BR112022014692A2 - Composição farmacêutica e composição farmacêutica para uso - Google Patents
Composição farmacêutica e composição farmacêutica para usoInfo
- Publication number
- BR112022014692A2 BR112022014692A2 BR112022014692A BR112022014692A BR112022014692A2 BR 112022014692 A2 BR112022014692 A2 BR 112022014692A2 BR 112022014692 A BR112022014692 A BR 112022014692A BR 112022014692 A BR112022014692 A BR 112022014692A BR 112022014692 A2 BR112022014692 A2 BR 112022014692A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- cancer
- aminolevulinic acid
- antiglioblastoma
- prophylaxis
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 7
- HJBHOJZDRYXROF-UHFFFAOYSA-N 5-amino-2-methyl-4-oxopentanoic acid Chemical compound OC(=O)C(C)CC(=O)CN HJBHOJZDRYXROF-UHFFFAOYSA-N 0.000 abstract 3
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 abstract 3
- 208000003174 Brain Neoplasms Diseases 0.000 abstract 2
- 229960002749 aminolevulinic acid Drugs 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 229960004191 artemisinin Drugs 0.000 abstract 2
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 abstract 2
- 229930101531 artemisinin Natural products 0.000 abstract 2
- FIHJKUPKCHIPAT-AHIGJZGOSA-N artesunate Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](OC(=O)CCC(O)=O)[C@@H]4C FIHJKUPKCHIPAT-AHIGJZGOSA-N 0.000 abstract 2
- 229940127089 cytotoxic agent Drugs 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- -1 artemisinin compound Chemical class 0.000 abstract 1
- 229960004991 artesunate Drugs 0.000 abstract 1
- 208000005017 glioblastoma Diseases 0.000 abstract 1
- 201000005787 hematologic cancer Diseases 0.000 abstract 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 abstract 1
- 201000007270 liver cancer Diseases 0.000 abstract 1
- 208000014018 liver neoplasm Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
COMPOSIÇÃO FARMACÊUTICA E COMPOSIÇÃO FARMACÊUTICA PARA USO. A presente invenção refere-se a uma composição farmacêutica compreendendo um composto de artemisinina e ácido 5-aminolevulínico ou ácido metil-5-aminolevulínico e pelo menos um agente quimioterapêutico, preferencialmente pelo menos uma droga antiglioblastoma. Esta composição farmacêutica é usada para a profilaxia e/ou tratamento de cânceres hematopoiéticos, câncer cerebral, câncer pancreático, câncer de fígado, câncer de mama e câncer de pulmão, tal como câncer de pulmão de células não pequenas. Preferencialmente, o presente pedido provê uma composição farmacêutica compreendendo artemisinina (1a) ou diidroarteminisina (1b) ou artesunato (1e) e ácido 5-aminolevulínico (2) ou ácido metil-5-aminolevulínico (2b) e pelo menos um agente quimioterapêutico, preferencialmente pelo menos uma droga antiglioblastoma para uso em profilaxia e/ou tratamento de câncer cerebral, particularmente glioblastoma.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20158341.6A EP3868372A1 (en) | 2020-02-19 | 2020-02-19 | A pharmaceutical combination of an artemisinin compound and a heme synthesis modulator for treating cancer |
| PCT/EP2021/054039 WO2021165405A1 (en) | 2020-02-19 | 2021-02-18 | A pharmaceutical combination of an artemisinin compound, 5-aminolevulinic acid or methyl-5-aminolevulinic acid and a chemotherapeutic agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022014692A2 true BR112022014692A2 (pt) | 2022-09-20 |
Family
ID=69779738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022014692A BR112022014692A2 (pt) | 2020-02-19 | 2021-02-18 | Composição farmacêutica e composição farmacêutica para uso |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230121771A1 (pt) |
| EP (2) | EP3868372A1 (pt) |
| JP (1) | JP2023514426A (pt) |
| KR (1) | KR20220143097A (pt) |
| CN (1) | CN114786661A (pt) |
| AU (1) | AU2021222339A1 (pt) |
| BR (1) | BR112022014692A2 (pt) |
| CA (1) | CA3165208A1 (pt) |
| DK (1) | DK3989961T3 (pt) |
| ES (1) | ES2972799T3 (pt) |
| FI (1) | FI3989961T3 (pt) |
| IL (1) | IL294856A (pt) |
| PL (1) | PL3989961T3 (pt) |
| PT (1) | PT3989961T (pt) |
| WO (1) | WO2021165405A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116981475A (zh) * | 2020-11-30 | 2023-10-31 | 索纳拉森斯股份有限公司 | 低级别肿瘤的代谢靶向 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996028412A1 (en) | 1995-03-10 | 1996-09-19 | Photocure As | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy |
| GB0018528D0 (en) | 2000-07-27 | 2000-09-13 | Photocure Asa | Compounds |
| GB0406917D0 (en) | 2004-03-26 | 2004-04-28 | Photocure Asa | Compounds |
| US10925963B2 (en) * | 2015-06-22 | 2021-02-23 | Washington University | Combination artemisinin and chemiluminescent photodynamic therapy and uses therefor |
| CN106527586B (zh) * | 2016-11-04 | 2019-09-06 | 吉林省北方医药有限责任公司 | 一种移动终端设备 |
| CN108570089B (zh) * | 2017-04-28 | 2019-10-29 | 云白药征武科技(上海)有限公司 | 双氢青蒿素-甾体结合物及其制备方法和应用 |
| GB201800736D0 (en) * | 2018-01-17 | 2018-02-28 | St Georges Hospital Medical School | Combination therapy for treatment of leukemia |
| CN108635581A (zh) * | 2018-05-23 | 2018-10-12 | 昆药集团股份有限公司 | 一种组合物及其在制备治疗肿瘤的药物中的应用 |
-
2020
- 2020-02-19 EP EP20158341.6A patent/EP3868372A1/en active Pending
-
2021
- 2021-02-18 WO PCT/EP2021/054039 patent/WO2021165405A1/en active Application Filing
- 2021-02-18 CN CN202180007033.7A patent/CN114786661A/zh active Pending
- 2021-02-18 PT PT217055417T patent/PT3989961T/pt unknown
- 2021-02-18 FI FIEP21705541.7T patent/FI3989961T3/fi active
- 2021-02-18 PL PL21705541.7T patent/PL3989961T3/pl unknown
- 2021-02-18 EP EP21705541.7A patent/EP3989961B1/en active Active
- 2021-02-18 CA CA3165208A patent/CA3165208A1/en active Pending
- 2021-02-18 AU AU2021222339A patent/AU2021222339A1/en active Pending
- 2021-02-18 US US17/801,021 patent/US20230121771A1/en active Pending
- 2021-02-18 KR KR1020227032196A patent/KR20220143097A/ko active Search and Examination
- 2021-02-18 ES ES21705541T patent/ES2972799T3/es active Active
- 2021-02-18 JP JP2022550755A patent/JP2023514426A/ja active Pending
- 2021-02-18 BR BR112022014692A patent/BR112022014692A2/pt unknown
- 2021-02-18 DK DK21705541.7T patent/DK3989961T3/da active
- 2021-02-18 IL IL294856A patent/IL294856A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN114786661A (zh) | 2022-07-22 |
| EP3868372A1 (en) | 2021-08-25 |
| ES2972799T3 (es) | 2024-06-17 |
| US20230121771A1 (en) | 2023-04-20 |
| KR20220143097A (ko) | 2022-10-24 |
| EP3989961A1 (en) | 2022-05-04 |
| IL294856A (en) | 2022-09-01 |
| AU2021222339A1 (en) | 2022-07-28 |
| CA3165208A1 (en) | 2021-08-26 |
| DK3989961T3 (da) | 2024-01-29 |
| PL3989961T3 (pl) | 2024-04-08 |
| FI3989961T3 (fi) | 2024-02-14 |
| EP3989961B1 (en) | 2023-11-22 |
| JP2023514426A (ja) | 2023-04-05 |
| WO2021165405A1 (en) | 2021-08-26 |
| PT3989961T (pt) | 2024-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023002090A1 (es) | Inhibidores de kras tricíclicos fusionados | |
| BRPI0608840B8 (pt) | composição farmacêutica compreendendo uma difenil uréia substituída por ômega-carboxiarila, e seu processo de preparação | |
| BR112023024646A2 (pt) | Composto tetacíclico fundido, método de preparação do mesmo e aplicação do mesmo na medicina | |
| BRPI0517104A (pt) | tratamento combinado com bortezomib e um inibidor de cinase de receptor de fator de crescimento epidérmico | |
| CO2021009882A2 (es) | Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer | |
| BRPI0510657A (pt) | tratamento com cisplatina e com um inibidor de egfr | |
| BRPI0511760A (pt) | tratamento com gemcitabina e um inibidor de egfr | |
| CO2018007674A2 (es) | Formulaciones para el tratamiento del cáncer de vejiga | |
| BR112015023922A2 (pt) | composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes | |
| BR112015016997A2 (pt) | composto, composição farmacêutica e método para o tratamento ou prevenção de câncer de mama | |
| RS20080167A (en) | Novel improved compositions for cancer therapy | |
| SA521422405B1 (ar) | Mat2a مثبطات أزا-غير متجانسة ثنائية الحلقة لـ وطرق الاستخدام لعلاج السرطان | |
| BRPI0607809A2 (pt) | uso de uma composição compreendendo nanopartìculas, composição e kit | |
| BR112016028641A2 (pt) | ?método para tratar câncer? | |
| UY37149A (es) | 2–amino–n–[7–metoxi–2,3–dihidroimidazo–[1,2–c]quinazolin–5–il]pirimidin–5–carboxamidas | |
| BRPI0517075A (pt) | uso de um inibidor de cinase de receptor de fator de crescimento epidérmico e radiação de ionização para tratamento de cáncer | |
| BRPI0511800A (pt) | tratamento com irinotecano (cpt-11) e um inibidor de egfr | |
| BR112022014692A2 (pt) | Composição farmacêutica e composição farmacêutica para uso | |
| BR112019022280A2 (pt) | tratamento de cânceres de her2 positivo | |
| BR112023022496A2 (pt) | Composto heterocíclico contendo nitrogênio, método de preparação do mesmo, e aplicação do mesmo em medicamentos | |
| RU2018107930A (ru) | Агонисты tlr4, их композиции и применение для лечения рака | |
| BR112018076821A2 (pt) | derivados de ftalazina como inibidores de parp1, parp2 e/ou tubulina úteis para o tratamento contra câncer | |
| PH12021550836A1 (en) | Intratumor injection formulation | |
| CO6430423A2 (es) | Combinaciones farmaceuticas que comprenden rdea119/bay 869766 para el tratamiento de canceres especificos | |
| BRPI0511780A (pt) | tratamento com oxoliplatina e um inibidor de egrf |